Merola, J. F.
Dennis, N.
Chakravarty, S. D.
Villacorta, R.
Mesana, L.
Lin, I.
Wang, Y.
Shawi, M.
Pacou, M.
Baker, T.
Peterson, S.
Funding for this research was provided by:
Janssen Pharmaceutica
Article History
Received: 11 February 2021
Revised: 11 February 2021
Accepted: 21 March 2021
First Online: 2 May 2021
Declarations
:
: The use of the IBM MarketScan® databases was reviewed by the New England Institution Review Board and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research.
: Not applicable.
: Not applicable.
: JFM is a consultant and/or investigator for Abbvie, Amgen, Bayer, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, BMS, and LEO Pharma. IL, TB, YW, and RV are employees of Janssen Pharmaceutical companies that manufacture products indicated for psoriasis and PsA. SDC, SP, and MS are employees of Janssen Scientific Affairs, LLC and shareholders of Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. ND, LM, and MP have no conflicts to disclose.